



PRESS RELEASE

*UPPSALA, SWEDEN
December 21, 2009*

Senzime seeking strategic alliance in the continuous, blood glucose monitoring field

TechGen International, Ltd. appointed as consultants to facilitate the process of Senzime securing a global, corporate partnering relationship.

During 2009, Senzime achieved significant success in developing its proprietary sensor for use in clinical diagnostics. In June, Senzime reported that its biosensor technology measures, effectively and continuously, blood glucose levels in a clinical setting, on patients in the intensive care unit. To date, four patients have been monitored with the sensor and the company continues to add to that base of clinical data. During the latter part of 2009, Senzime has produced data to show sensor longevity, stability and precision for measurements in whole blood - all key parameters in a clinical setting. In-vitro data derived using human blood complements the clinical trial data.

To support final development of the sensor instrument and to provide the marketing channel for the product, Senzime is seeking to identify and establish a commercial relationship with a corporate partner – a company already present in, or poised to enter into, the critical care blood glucose monitoring segment of the clinical diagnostics market world-wide.

Based on the solid progress and accomplishments made in 2009 the Company considers that 2010 is the opportune time to establish a strategic partnership, to join the process of final product development and the subsequent progression to commercialisation/marketing. As a key part of this strategic development Senzime has engaged TechGen International, Ltd. in an advisory capacity to facilitate the process.

“We are pleased to have engaged the services of a well reputed firm with significant international strategic experience in our target market segment. Our relationship with TechGen will extend our reach and strengthen our capabilities as we showcase our unique sensor technology to some of the world’s most important players in the clinical diagnostics industry. These are exciting times”, states Staffan Boström, CEO at Senzime.

“Having worked in this field for some years, I am impressed by what Senzime has achieved. The Company has developed innovative technology which addresses an important critical care need in today’s clinical diagnostics market and which I feel sure will be of compelling interest to the leading industry players”, comments Alan Hulme, CEO of TechGen International, Ltd.

Senzime AB (publ)
Vallvägen 4 A, 756 51 Uppsala, Sweden
Phone +46 (0)18 51 56 40 - Fax +46 (0)18 51 56 30
www.senzime.com



Clinical Diagnostics Market Focus

Senzime has developed unique sensor technology for bed-side patient monitoring. The primary focus is to launch an instrumented system for continuous monitoring of the blood glucose levels of patients in the operating theatre and in intensive care units. Due to the adoption of tight glycaemic control schemes in these settings, it is becoming crucial for hospitals to have, or to seek to put in place, systems for continuous measurement of glucose in whole blood.

US based industry analyst Frost & Sullivan (2005) estimates that 6,000 ICU's in the US between them manage roughly 55,000 patients per day. Continuous glucose checks on all patients represent a sizeable and under-satisfied market need. There is significant interest by established industry players in this market niche.

Senzime has demonstrated that the Company has a powerful contribution to make towards addressing this diagnostic need.

Senzime AB (publ)

Uppsala based Senzime, founded in 1999, has developed a biosensor with the capability to continuously and automatically monitor critical components in complex biological fluids. The need for such on-line measurements is increasing in a range of industries, for example in health care and in pharmaceutical production.

Senzime's first product offering will consist of a measurement instrument, in combination with disposable sensor units, designed for the automated, continuous monitoring of glucose in whole blood. The first patient was monitored by a Senzime instrument in June 2009 at the Uppsala University Hospital.

In parallel, the Company is working on developments for applications in the pharmaceutical production field (bioreactors/fermentation) for detection of glucose and other analytes.

The company's largest shareholders are members of the Crafoord family, perhaps best known in this field for their key role in having developed the Swedish medical devices company Gambro.

Senzime is a publicly listed company and its shares trade on the Swedish AktieTorget market (www.aktietorget.se).

TechGen International Ltd.

TechGen International, Ltd. is a London based international management consultancy providing a range of corporate development services, primarily to commercialisation/expansion phase, venture backed companies in the life sciences sector.

For more information, please visit www.senzime.com or contact:

Staffan Boström, CEO
Tel. +46 (0)18 51 56 40
Mobile +46 (0)70 607 10 02

Senzime AB (publ)
Vallvägen 4 A, 756 51 Uppsala, Sweden
Phone +46 (0)18 51 56 40 - Fax +46 (0)18 51 56 30
www.senzime.com